A new biotech has been launched by GT Healthcare Capital Partners, a life science-focused private equity partnership specializing in capital investments and market scalability in the China region.
The new company, GT Apeiron Therapeutics, is an AI-driven drug development company in Shanghai with financial backing of $27 million.
From the outset, GT Apeiron Therapeutics will collaborate with UK-based Exscientia, which calls itself a world-leading AI-driven drug discovery company.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze